Less frequent dosing of <scp>GLP</scp>‐1 receptor agonists as a viable weight maintenance strategy

Our findings support the hypothesis that less frequent administration of incretin mimetics can be a viable and cost-saving long-term weight maintenance strategy in conjunction with sustained lifestyle modification. Further research is warranted to validate the effectiveness of this off-label approach, define optimal dosing regimens to meet individual patient needs, and evaluate the cost-benefit implications.